Evidence map›Paper›PMID 38353855›Full record

ArticleJournal of cancer survivorship : research and practice2025

Chronic health conditions after childhood Langerhans cell histiocytosis: Results from the Swiss Childhood Cancer Survivor Study.

Tomáš Sláma, Luzius Mader, Maša Žarković, Reta Malär, Alexandra Schifferli, Nicolas X von der Weid, Claudia E Kuehni, Christina Schindera

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03297034 (Swiss Childhood Cancer Survivor Study), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03297034 recruitingnot on this map

Swiss Childhood Cancer Survivor Study (SCCSS)

Typeobservational_patient_registrySponsorUniversity of BernRan2007 to 2050Enrolled4,136ConditionsChildhood Cancer
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Tomáš SlámaChildhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-4422-479X
Luzius MaderChildhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0001-5613-4356
Maša ŽarkovićChildhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-0220-5566
Reta MalärDepartment of Paediatrics, Cantonal Hospital Graubuenden, Chur, Switzerland.
Alexandra SchifferliDivision of Paediatric Oncology/Haematology, University Children's Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0001-9459-8709
Nicolas X von der WeidDivision of Paediatric Oncology/Haematology, University Children's Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0002-9555-3817
Claudia E Kuehni *Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0001-8957-2002
Christina Schindera *Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. christina.schindera@unibe.ch.ORCID 0000-0002-4511-287X
University of Bern · CHUniversity of Basel · CH

Funding

Krebsliga Schweiz KLS/KFS-4825-01-2019Swiss Cancer Research Foundation KFS-5027-02-2020Swiss Cancer Research Foundation KFS-5302-02-2021
6 · The paper itself

Abstract

purposeLangerhans cell histiocytosis (LCH) is a rare disease characterized by dysregulated proliferation of myeloid marrow progenitors and subsequent organ infiltration. While LCH is associated with a favorable prognosis, some survivors may develop chronic health conditions (CHC) because of the disease. In this study, we aimed to assess the spectrum and prevalence of CHC among LCH survivors compared with siblings and identify factors associated with the development of CHC.

methodsThe Swiss Childhood Cancer Survivor Study sent questionnaires to all ≥ 5-year LCH survivors registered in the Swiss Childhood Cancer Registry and diagnosed between 1976 and 2015. Siblings also received similar questionnaires. We compared CHC prevalence between LCH survivors and siblings and used logistic regression to identify determinants of CHC.

resultsA total of 123 LCH survivors participated in the study, with a response rate of 69%. Median time since diagnosis was 13 years (interquartile range 9-20). Among LCH survivors, 59% had at least one CHC. Cardiovascular (13% vs. 6%), endocrine (15% vs. 2%), musculoskeletal (22% vs. 13%), and digestive (15% vs. 8%) CHC were more common among LCH survivors compared to siblings (all p < 0.05). Factors most strongly associated with the occurrence of CHC were multisystem LCH, multifocal bone involvement, and involvement of the pituitary gland.

conclusionsMore than half of long-term LCH survivors suffered from one or more CHC and were affected considerably more than siblings. IMPLICATIONS FOR CANCER SURVIVORS: LCH survivors in follow-up care should be screened especially for cardiovascular, endocrine, musculoskeletal, and digestive conditions.

Indexed as

Cancer SurvivorsHistiocytosis, Langerhans-CellAdolescentAdultChildChild, PreschoolChronic DiseaseFemaleHumansInfantMalePrevalenceRegistriesSwitzerlandYoung AdultChildhood cancer survivorsChronic health conditionsCohort studyLangerhans cell histiocytosisLate effectsRare disease

Identifiers

PMID38353855
PMCPMC12283886
OpenAlexW4391809615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.